nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.101	0.215	CbGbCtD
Rivaroxaban—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0681	0.145	CbGbCtD
Rivaroxaban—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.065	0.139	CbGbCtD
Rivaroxaban—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0579	0.124	CbGbCtD
Rivaroxaban—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0567	0.121	CbGbCtD
Rivaroxaban—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0535	0.114	CbGbCtD
Rivaroxaban—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.034	0.0726	CbGbCtD
Rivaroxaban—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0321	0.0685	CbGbCtD
Rivaroxaban—F10—Common Pathway—SERPINE2—chronic obstructive pulmonary disease	0.0158	0.0804	CbGpPWpGaD
Rivaroxaban—F10—Intrinsic Pathway—SERPINE2—chronic obstructive pulmonary disease	0.0135	0.0684	CbGpPWpGaD
Rivaroxaban—CYP2J2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.0115	0.0584	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.0107	0.0542	CbGpPWpGaD
Rivaroxaban—F10—Formation of Fibrin Clot (Clotting Cascade)—SERPINE2—chronic obstructive pulmonary disease	0.0091	0.0462	CbGpPWpGaD
Rivaroxaban—CYP2J2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.00837	0.0425	CbGpPWpGaD
Rivaroxaban—CYP2J2—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.00554	0.0281	CbGpPWpGaD
Rivaroxaban—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00468	0.0237	CbGpPWpGaD
Rivaroxaban—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00414	0.021	CbGpPWpGaD
Rivaroxaban—CYP2J2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00402	0.0204	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—PLAUR—chronic obstructive pulmonary disease	0.00381	0.0193	CbGpPWpGaD
Rivaroxaban—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00338	0.0172	CbGpPWpGaD
Rivaroxaban—F10—Blood Clotting Cascade—PLAU—chronic obstructive pulmonary disease	0.00333	0.0169	CbGpPWpGaD
Rivaroxaban—F10—Complement and Coagulation Cascades—SERPINA1—chronic obstructive pulmonary disease	0.00308	0.0156	CbGpPWpGaD
Rivaroxaban—CYP2J2—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00284	0.0144	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—PLAU—chronic obstructive pulmonary disease	0.00267	0.0136	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00266	0.0135	CbGpPWpGaD
Rivaroxaban—F10—Blood Clotting Cascade—SERPINE1—chronic obstructive pulmonary disease	0.00258	0.0131	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.00235	0.0119	CbGpPWpGaD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.0023	0.0117	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.00227	0.0115	CbGpPWpGaD
Rivaroxaban—F10—Complement and Coagulation Cascades—PLAUR—chronic obstructive pulmonary disease	0.00216	0.0109	CbGpPWpGaD
Rivaroxaban—CYP2J2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00207	0.0105	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00193	0.0098	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.00186	0.00945	CbGpPWpGaD
Rivaroxaban—F10—Post-translational protein modification—MUC5AC—chronic obstructive pulmonary disease	0.00182	0.00924	CbGpPWpGaD
Rivaroxaban—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00172	0.00871	CbGpPWpGaD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.00167	0.00847	CbGpPWpGaD
Rivaroxaban—CYP3A5—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.00166	0.00843	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.00165	0.00836	CbGpPWpGaD
Rivaroxaban—CYP3A5—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.0016	0.00809	CbGpPWpGaD
Rivaroxaban—F10—Post-translational protein modification—MUC1—chronic obstructive pulmonary disease	0.00155	0.00785	CbGpPWpGaD
Rivaroxaban—CYP3A5—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00153	0.00778	CbGpPWpGaD
Rivaroxaban—F10—Complement and Coagulation Cascades—PLAU—chronic obstructive pulmonary disease	0.00151	0.00768	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00135	0.00687	CbGpPWpGaD
Rivaroxaban—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.00132	0.00668	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.00119	0.00604	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.00118	0.00597	CbGpPWpGaD
Rivaroxaban—F10—Complement and Coagulation Cascades—SERPINE1—chronic obstructive pulmonary disease	0.00117	0.00594	CbGpPWpGaD
Rivaroxaban—CYP3A5—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00116	0.00588	CbGpPWpGaD
Rivaroxaban—CYP3A5—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00111	0.00565	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	0.0011	0.00557	CbGpPWpGaD
Rivaroxaban—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00102	0.00518	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.00099	0.00502	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000976	0.00495	CbGpPWpGaD
Rivaroxaban—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000967	0.00289	CcSEcCtD
Rivaroxaban—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.000967	0.00289	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000965	0.00288	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000965	0.00288	CcSEcCtD
Rivaroxaban—Contusion—Prednisone—chronic obstructive pulmonary disease	0.000961	0.00287	CcSEcCtD
Rivaroxaban—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000961	0.00287	CcSEcCtD
Rivaroxaban—F10—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	0.00096	0.00487	CbGpPWpGaD
Rivaroxaban—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000953	0.00285	CcSEcCtD
Rivaroxaban—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.000947	0.00283	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000945	0.00282	CcSEcCtD
Rivaroxaban—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000945	0.00282	CcSEcCtD
Rivaroxaban—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000944	0.00282	CcSEcCtD
Rivaroxaban—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000942	0.00281	CcSEcCtD
Rivaroxaban—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000939	0.0028	CcSEcCtD
Rivaroxaban—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000938	0.0028	CcSEcCtD
Rivaroxaban—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000936	0.0028	CcSEcCtD
Rivaroxaban—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000934	0.00279	CcSEcCtD
Rivaroxaban—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000927	0.00277	CcSEcCtD
Rivaroxaban—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000924	0.00276	CcSEcCtD
Rivaroxaban—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.00092	0.00275	CcSEcCtD
Rivaroxaban—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000917	0.00274	CcSEcCtD
Rivaroxaban—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000915	0.00273	CcSEcCtD
Rivaroxaban—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000913	0.00273	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000911	0.00272	CcSEcCtD
Rivaroxaban—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000901	0.00269	CcSEcCtD
Rivaroxaban—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000901	0.00269	CcSEcCtD
Rivaroxaban—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000896	0.00268	CcSEcCtD
Rivaroxaban—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000896	0.00268	CcSEcCtD
Rivaroxaban—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00089	0.00266	CcSEcCtD
Rivaroxaban—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000887	0.0045	CbGpPWpGaD
Rivaroxaban—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.00088	0.00263	CcSEcCtD
Rivaroxaban—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000877	0.00262	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Prednisolone—chronic obstructive pulmonary disease	0.000877	0.00262	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000865	0.00258	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000865	0.00258	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—MUC5AC—chronic obstructive pulmonary disease	0.000864	0.00438	CbGpPWpGaD
Rivaroxaban—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000851	0.00254	CcSEcCtD
Rivaroxaban—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000851	0.00254	CcSEcCtD
Rivaroxaban—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000851	0.00254	CcSEcCtD
Rivaroxaban—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000846	0.00253	CcSEcCtD
Rivaroxaban—Malaise—Formoterol—chronic obstructive pulmonary disease	0.00084	0.00251	CcSEcCtD
Rivaroxaban—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.00084	0.00251	CcSEcCtD
Rivaroxaban—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.000838	0.0025	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000837	0.00425	CbGpPWpGaD
Rivaroxaban—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000834	0.00249	CcSEcCtD
Rivaroxaban—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000829	0.00248	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000826	0.00419	CbGpPWpGaD
Rivaroxaban—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000817	0.00244	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000816	0.00244	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000814	0.00413	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000814	0.00243	CcSEcCtD
Rivaroxaban—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000807	0.00409	CbGpPWpGaD
Rivaroxaban—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000806	0.00241	CcSEcCtD
Rivaroxaban—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000804	0.0024	CcSEcCtD
Rivaroxaban—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000794	0.00237	CcSEcCtD
Rivaroxaban—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000793	0.00237	CcSEcCtD
Rivaroxaban—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000793	0.00237	CcSEcCtD
Rivaroxaban—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000793	0.00237	CcSEcCtD
Rivaroxaban—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00079	0.00236	CcSEcCtD
Rivaroxaban—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000789	0.00236	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000788	0.00235	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000788	0.00235	CcSEcCtD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000788	0.00399	CbGpPWpGaD
Rivaroxaban—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000784	0.00234	CcSEcCtD
Rivaroxaban—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000784	0.00234	CcSEcCtD
Rivaroxaban—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000776	0.00232	CcSEcCtD
Rivaroxaban—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000776	0.00232	CcSEcCtD
Rivaroxaban—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000773	0.00231	CcSEcCtD
Rivaroxaban—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000773	0.00392	CbGpPWpGaD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000772	0.00231	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000771	0.0023	CcSEcCtD
Rivaroxaban—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.00076	0.00227	CcSEcCtD
Rivaroxaban—Oedema—Formoterol—chronic obstructive pulmonary disease	0.00076	0.00227	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.00076	0.00227	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.00076	0.00227	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000759	0.00385	CbGpPWpGaD
Rivaroxaban—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.000758	0.00227	CcSEcCtD
Rivaroxaban—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000755	0.00226	CcSEcCtD
Rivaroxaban—Infection—Formoterol—chronic obstructive pulmonary disease	0.000755	0.00226	CcSEcCtD
Rivaroxaban—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000749	0.00224	CcSEcCtD
Rivaroxaban—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000749	0.00224	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000748	0.00379	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000746	0.00223	CcSEcCtD
Rivaroxaban—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000746	0.00223	CcSEcCtD
Rivaroxaban—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000745	0.00223	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000745	0.00223	CcSEcCtD
Rivaroxaban—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000745	0.00223	CcSEcCtD
Rivaroxaban—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000742	0.00222	CcSEcCtD
Rivaroxaban—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000742	0.00222	CcSEcCtD
Rivaroxaban—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000742	0.00376	CbGpPWpGaD
Rivaroxaban—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00074	0.00221	CcSEcCtD
Rivaroxaban—Infection—Montelukast—chronic obstructive pulmonary disease	0.00074	0.00221	CcSEcCtD
Rivaroxaban—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000739	0.00221	CcSEcCtD
Rivaroxaban—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000739	0.00221	CcSEcCtD
Rivaroxaban—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000736	0.0022	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—MUC1—chronic obstructive pulmonary disease	0.000735	0.00373	CbGpPWpGaD
Rivaroxaban—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000733	0.00219	CcSEcCtD
Rivaroxaban—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00073	0.00218	CcSEcCtD
Rivaroxaban—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000724	0.00216	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000719	0.00365	CbGpPWpGaD
Rivaroxaban—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000718	0.00214	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000718	0.00214	CcSEcCtD
Rivaroxaban—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000713	0.00362	CbGpPWpGaD
Rivaroxaban—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000713	0.00213	CcSEcCtD
Rivaroxaban—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000711	0.00212	CcSEcCtD
Rivaroxaban—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000711	0.00212	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000709	0.0036	CbGpPWpGaD
Rivaroxaban—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000707	0.00211	CcSEcCtD
Rivaroxaban—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000706	0.00211	CcSEcCtD
Rivaroxaban—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000704	0.0021	CcSEcCtD
Rivaroxaban—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000701	0.00209	CcSEcCtD
Rivaroxaban—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000697	0.00208	CcSEcCtD
Rivaroxaban—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000694	0.00207	CcSEcCtD
Rivaroxaban—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000684	0.00204	CcSEcCtD
Rivaroxaban—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000678	0.00203	CcSEcCtD
Rivaroxaban—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000678	0.00203	CcSEcCtD
Rivaroxaban—CYP3A5—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000678	0.00344	CbGpPWpGaD
Rivaroxaban—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000671	0.002	CcSEcCtD
Rivaroxaban—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000669	0.002	CcSEcCtD
Rivaroxaban—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000669	0.002	CcSEcCtD
Rivaroxaban—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000667	0.00199	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000663	0.00336	CbGpPWpGaD
Rivaroxaban—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000661	0.00197	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000657	0.00196	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000657	0.00196	CcSEcCtD
Rivaroxaban—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000656	0.00196	CcSEcCtD
Rivaroxaban—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000656	0.00196	CcSEcCtD
Rivaroxaban—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000656	0.00196	CcSEcCtD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000654	0.00332	CbGpPWpGaD
Rivaroxaban—Pain—Formoterol—chronic obstructive pulmonary disease	0.00065	0.00194	CcSEcCtD
Rivaroxaban—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00065	0.00194	CcSEcCtD
Rivaroxaban—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00065	0.00194	CcSEcCtD
Rivaroxaban—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00065	0.00194	CcSEcCtD
Rivaroxaban—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000644	0.00327	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000643	0.00192	CcSEcCtD
Rivaroxaban—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000642	0.00192	CcSEcCtD
Rivaroxaban—F10—Post-translational protein modification—PLAUR—chronic obstructive pulmonary disease	0.000641	0.00325	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00064	0.00191	CcSEcCtD
Rivaroxaban—Pain—Montelukast—chronic obstructive pulmonary disease	0.000637	0.0019	CcSEcCtD
Rivaroxaban—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000635	0.0019	CcSEcCtD
Rivaroxaban—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000632	0.00189	CcSEcCtD
Rivaroxaban—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00063	0.00188	CcSEcCtD
Rivaroxaban—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000629	0.00188	CcSEcCtD
Rivaroxaban—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000627	0.00187	CcSEcCtD
Rivaroxaban—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000627	0.00187	CcSEcCtD
Rivaroxaban—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000626	0.00187	CcSEcCtD
Rivaroxaban—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000623	0.00186	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000622	0.00186	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000622	0.00186	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00062	0.00185	CcSEcCtD
Rivaroxaban—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000619	0.00185	CcSEcCtD
Rivaroxaban—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000619	0.00314	CbGpPWpGaD
Rivaroxaban—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000614	0.00183	CcSEcCtD
Rivaroxaban—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000614	0.00183	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000609	0.00182	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000609	0.00182	CcSEcCtD
Rivaroxaban—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000609	0.00182	CcSEcCtD
Rivaroxaban—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000604	0.0018	CcSEcCtD
Rivaroxaban—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000604	0.0018	CcSEcCtD
Rivaroxaban—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000601	0.0018	CcSEcCtD
Rivaroxaban—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000601	0.0018	CcSEcCtD
Rivaroxaban—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000599	0.00179	CcSEcCtD
Rivaroxaban—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000594	0.00177	CcSEcCtD
Rivaroxaban—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000594	0.00177	CcSEcCtD
Rivaroxaban—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000594	0.00177	CcSEcCtD
Rivaroxaban—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000592	0.00177	CcSEcCtD
Rivaroxaban—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000592	0.00177	CcSEcCtD
Rivaroxaban—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00059	0.00176	CcSEcCtD
Rivaroxaban—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000589	0.00176	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000587	0.00175	CcSEcCtD
Rivaroxaban—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000586	0.00297	CbGpPWpGaD
Rivaroxaban—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000583	0.00174	CcSEcCtD
Rivaroxaban—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.00058	0.00173	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—APIP—chronic obstructive pulmonary disease	0.000579	0.00293	CbGpPWpGaD
Rivaroxaban—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.00057	0.0017	CcSEcCtD
Rivaroxaban—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000568	0.0017	CcSEcCtD
Rivaroxaban—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00056	0.00167	CcSEcCtD
Rivaroxaban—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00056	0.00167	CcSEcCtD
Rivaroxaban—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00056	0.00167	CcSEcCtD
Rivaroxaban—F10—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	0.000552	0.0028	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000549	0.00164	CcSEcCtD
Rivaroxaban—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000546	0.00163	CcSEcCtD
Rivaroxaban—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000546	0.00163	CcSEcCtD
Rivaroxaban—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000539	0.00273	CbGpPWpGaD
Rivaroxaban—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000538	0.00161	CcSEcCtD
Rivaroxaban—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000538	0.00161	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000537	0.00272	CbGpPWpGaD
Rivaroxaban—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000534	0.0016	CcSEcCtD
Rivaroxaban—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000529	0.00158	CcSEcCtD
Rivaroxaban—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000527	0.00157	CcSEcCtD
Rivaroxaban—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00052	0.00155	CcSEcCtD
Rivaroxaban—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00052	0.00155	CcSEcCtD
Rivaroxaban—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000518	0.00263	CbGpPWpGaD
Rivaroxaban—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000515	0.00154	CcSEcCtD
Rivaroxaban—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00051	0.00152	CcSEcCtD
Rivaroxaban—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000508	0.00152	CcSEcCtD
Rivaroxaban—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000503	0.0015	CcSEcCtD
Rivaroxaban—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000503	0.0015	CcSEcCtD
Rivaroxaban—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000493	0.00147	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000492	0.00249	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000491	0.00147	CcSEcCtD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000485	0.00246	CbGpPWpGaD
Rivaroxaban—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000484	0.00144	CcSEcCtD
Rivaroxaban—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000484	0.00144	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000481	0.00244	CbGpPWpGaD
Rivaroxaban—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000479	0.00143	CcSEcCtD
Rivaroxaban—Rash—Formoterol—chronic obstructive pulmonary disease	0.000479	0.00143	CcSEcCtD
Rivaroxaban—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000479	0.00143	CcSEcCtD
Rivaroxaban—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000479	0.00143	CcSEcCtD
Rivaroxaban—F10—Hemostasis—TGFB2—chronic obstructive pulmonary disease	0.000478	0.00243	CbGpPWpGaD
Rivaroxaban—Headache—Formoterol—chronic obstructive pulmonary disease	0.000476	0.00142	CcSEcCtD
Rivaroxaban—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000476	0.00142	CcSEcCtD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000475	0.00241	CbGpPWpGaD
Rivaroxaban—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000475	0.00142	CcSEcCtD
Rivaroxaban—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000474	0.00141	CcSEcCtD
Rivaroxaban—Rash—Montelukast—chronic obstructive pulmonary disease	0.00047	0.0014	CcSEcCtD
Rivaroxaban—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000469	0.0014	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000468	0.0014	CcSEcCtD
Rivaroxaban—Headache—Montelukast—chronic obstructive pulmonary disease	0.000467	0.00139	CcSEcCtD
Rivaroxaban—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000461	0.00138	CcSEcCtD
Rivaroxaban—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000457	0.00136	CcSEcCtD
Rivaroxaban—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000455	0.00136	CcSEcCtD
Rivaroxaban—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000453	0.00135	CcSEcCtD
Rivaroxaban—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000453	0.00135	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.000452	0.00229	CbGpPWpGaD
Rivaroxaban—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000452	0.00135	CcSEcCtD
Rivaroxaban—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000452	0.00135	CcSEcCtD
Rivaroxaban—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000452	0.00135	CcSEcCtD
Rivaroxaban—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00045	0.00134	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000448	0.00227	CbGpPWpGaD
Rivaroxaban—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000444	0.00132	CcSEcCtD
Rivaroxaban—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000442	0.00132	CcSEcCtD
Rivaroxaban—F10—Hemostasis—HDAC2—chronic obstructive pulmonary disease	0.000429	0.00218	CbGpPWpGaD
Rivaroxaban—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000427	0.00127	CcSEcCtD
Rivaroxaban—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000424	0.00127	CcSEcCtD
Rivaroxaban—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000423	0.00126	CcSEcCtD
Rivaroxaban—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000421	0.00126	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000414	0.00124	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000413	0.00209	CbGpPWpGaD
Rivaroxaban—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000412	0.00123	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000412	0.00123	CcSEcCtD
Rivaroxaban—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000405	0.00121	CcSEcCtD
Rivaroxaban—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000402	0.0012	CcSEcCtD
Rivaroxaban—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000394	0.00118	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00039	0.00198	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PLAUR—chronic obstructive pulmonary disease	0.000387	0.00196	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000383	0.00194	CbGpPWpGaD
Rivaroxaban—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000382	0.00114	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000381	0.00193	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000381	0.00193	CbGpPWpGaD
Rivaroxaban—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.00038	0.00114	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	0.00038	0.00193	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GC—chronic obstructive pulmonary disease	0.000373	0.00189	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.000359	0.00182	CbGpPWpGaD
Rivaroxaban—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000352	0.00105	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000347	0.00176	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000343	0.00174	CbGpPWpGaD
Rivaroxaban—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.00034	0.00102	CcSEcCtD
Rivaroxaban—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000339	0.00101	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000339	0.00172	CbGpPWpGaD
Rivaroxaban—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000339	0.00101	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—ACE—chronic obstructive pulmonary disease	0.000339	0.00172	CbGpPWpGaD
Rivaroxaban—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000335	0.001	CcSEcCtD
Rivaroxaban—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000331	0.000988	CcSEcCtD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.00033	0.00167	CbGpPWpGaD
Rivaroxaban—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000329	0.000982	CcSEcCtD
Rivaroxaban—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000327	0.000977	CcSEcCtD
Rivaroxaban—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000322	0.000963	CcSEcCtD
Rivaroxaban—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000315	0.0016	CbGpPWpGaD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.00031	0.000926	CcSEcCtD
Rivaroxaban—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000308	0.000921	CcSEcCtD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000308	0.00156	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000307	0.00156	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—PLAUR—chronic obstructive pulmonary disease	0.000304	0.00154	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000304	0.00154	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000303	0.000906	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000299	0.000894	CcSEcCtD
Rivaroxaban—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000299	0.000894	CcSEcCtD
Rivaroxaban—Infection—Prednisone—chronic obstructive pulmonary disease	0.000297	0.000888	CcSEcCtD
Rivaroxaban—Shock—Prednisone—chronic obstructive pulmonary disease	0.000294	0.00088	CcSEcCtD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000294	0.00149	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000293	0.000877	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	0.000292	0.00148	CbGpPWpGaD
Rivaroxaban—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000292	0.000873	CcSEcCtD
Rivaroxaban—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000291	0.000868	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000285	0.00145	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000281	0.00143	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000277	0.0014	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—MMP1—chronic obstructive pulmonary disease	0.000276	0.0014	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	0.000276	0.0014	CbGpPWpGaD
Rivaroxaban—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000272	0.000814	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	0.000272	0.00138	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PLAU—chronic obstructive pulmonary disease	0.000271	0.00138	CbGpPWpGaD
Rivaroxaban—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000263	0.000787	CcSEcCtD
Rivaroxaban—Rash—Prednisolone—chronic obstructive pulmonary disease	0.00026	0.000776	CcSEcCtD
Rivaroxaban—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000259	0.000775	CcSEcCtD
Rivaroxaban—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000258	0.000771	CcSEcCtD
Rivaroxaban—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000258	0.000771	CcSEcCtD
Rivaroxaban—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000256	0.000764	CcSEcCtD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.00025	0.00127	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—NOS2—chronic obstructive pulmonary disease	0.000249	0.00126	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000247	0.000737	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000245	0.000731	CcSEcCtD
Rivaroxaban—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000245	0.000731	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000238	0.00121	CbGpPWpGaD
Rivaroxaban—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000238	0.00071	CcSEcCtD
Rivaroxaban—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000237	0.000707	CcSEcCtD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000235	0.00119	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000229	0.00116	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000224	0.00113	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000221	0.00112	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.00022	0.000659	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000219	0.00111	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—MMP1—chronic obstructive pulmonary disease	0.000217	0.0011	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000216	0.00109	CbGpPWpGaD
Rivaroxaban—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000215	0.000641	CcSEcCtD
Rivaroxaban—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000212	0.000632	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—LEP—chronic obstructive pulmonary disease	0.00021	0.00107	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	0.00021	0.00106	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—ALB—chronic obstructive pulmonary disease	0.000209	0.00106	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000207	0.00105	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000205	0.000612	CcSEcCtD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000204	0.00104	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000204	0.00103	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000201	0.00102	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—NOS3—chronic obstructive pulmonary disease	0.0002	0.00102	CbGpPWpGaD
Rivaroxaban—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000198	0.000591	CcSEcCtD
Rivaroxaban—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.00019	0.000568	CcSEcCtD
Rivaroxaban—Rash—Prednisone—chronic obstructive pulmonary disease	0.000189	0.000564	CcSEcCtD
Rivaroxaban—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000189	0.000563	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	0.000188	0.000952	CbGpPWpGaD
Rivaroxaban—Headache—Prednisone—chronic obstructive pulmonary disease	0.000187	0.00056	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000184	0.000932	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000181	0.00092	CbGpPWpGaD
Rivaroxaban—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000178	0.000531	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000169	0.000858	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.000168	0.000853	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—APIP—chronic obstructive pulmonary disease	0.000167	0.000846	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.000161	0.000818	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.00016	0.000809	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000158	0.0008	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	0.000158	0.0008	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—VEGFA—chronic obstructive pulmonary disease	0.000144	0.000732	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000141	0.000716	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CXCL8—chronic obstructive pulmonary disease	0.00014	0.000709	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000139	0.000706	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	0.000137	0.000692	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000133	0.000673	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TGFB1—chronic obstructive pulmonary disease	0.000132	0.000672	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000131	0.000663	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.00013	0.000658	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	0.000126	0.000638	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	0.000125	0.000636	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000123	0.000624	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	0.000117	0.000593	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000111	0.000561	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.00011	0.00056	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000109	0.000553	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—chronic obstructive pulmonary disease	0.000109	0.000553	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	0.000107	0.000545	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000102	0.000516	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.0001	0.000508	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.99e-05	0.000507	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	9.64e-05	0.000489	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	9.51e-05	0.000482	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ALB—chronic obstructive pulmonary disease	8.36e-05	0.000424	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.34e-05	0.000423	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	8.11e-05	0.000411	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—NOS3—chronic obstructive pulmonary disease	8e-05	0.000406	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	7.75e-05	0.000393	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.54e-05	0.000382	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	6.74e-05	0.000342	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	6.47e-05	0.000328	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	6.18e-05	0.000314	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	6.06e-05	0.000308	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.87e-05	0.000298	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	5.8e-05	0.000294	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	5.78e-05	0.000293	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	5.3e-05	0.000269	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.14e-05	0.00026	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	5.09e-05	0.000258	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	5e-05	0.000253	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.88e-05	0.000247	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.64e-05	0.000236	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.43e-05	0.000225	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	4.38e-05	0.000222	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.07e-05	0.000206	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.01e-05	0.000204	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	4e-05	0.000203	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.88e-05	0.000197	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.74e-05	0.00019	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.68e-05	0.000187	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.55e-05	0.00018	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.07e-05	0.000156	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.03e-05	0.000154	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.82e-05	0.000143	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.73e-05	0.000138	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	2.7e-05	0.000137	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.68e-05	0.000136	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	2.46e-05	0.000125	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	2.41e-05	0.000122	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	2.31e-05	0.000117	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.27e-05	0.000115	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.89e-05	9.59e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.87e-05	9.46e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	1.82e-05	9.22e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.74e-05	8.82e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.74e-05	8.82e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.65e-05	8.36e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.12e-05	5.68e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.07e-05	5.43e-05	CbGpPWpGaD
